文献速递神经肿瘤脊柱脊髓外科

低级别脊髓星形细胞瘤的最佳治疗策略:日本神经脊柱学会的多中心回顾性分析

Optimal treatment strategy for low-grade spinal cord astrocytoma: a retrospective, multicenter analysis by the Neurospinal Society of Japan.
PubMed 文献 · J Neurosurg Spine · 2024-09-20

日本神经脊柱学会(NSJ)在58个中心1033例脊髓髓内肿瘤手术病例中纳入57例弥漫性星形细胞瘤(WHO II级)患者进行回顾性分析,比较单纯手术、辅助放疗和辅助放化疗的疗效。结果显示单纯手术或手术加放疗的总生存和无进展生存显著长于辅助放化疗,MIB-1标记指数低于4.0%者单纯手术预后较好。

要点

  • 单纯手术或手术加放疗的总生存和无进展生存显著长于辅助放化疗。
  • MIB-1标记指数低于4.0%是预测单纯手术获得较长生存的最佳临界值。
  • 肿瘤切除程度与较长生存趋势相关,术后神经功能恶化呈相反顺序。

核心结论

  • 脊髓星形细胞瘤的最佳治疗是在不造成神经功能损害的前提下最大程度切除肿瘤。
  • 当MIB-1标记指数低于4.0%且仍有肿瘤残留时,等待观察是最佳策略。
  • 若MIB-1标记指数高于4.0%,推荐局部放射治疗。
  • 不推荐辅助化疗用于II级脊髓星形细胞瘤的治疗。

研究设计与样本

  • 日本神经脊柱学会(NSJ)主导的多中心回顾性分析,纳入58个中心1033例连续手术治疗的脊髓髓内肿瘤病例中的57例弥漫性星形细胞瘤(WHO II级)患者。

主要发现

  • 治疗方式包括单纯手术30例、辅助放疗13例、辅助放化疗13例,1例未手术者被排除在生存分析之外。
  • 单纯手术或手术加放疗的总生存和无进展生存显著长于辅助放化疗。
  • 接受放疗的患者MIB-1标记指数高于单纯手术患者。
  • 肿瘤切除程度与较长生存趋势相关,术后神经功能恶化呈相反顺序。
  • 辅助放化疗在全部病例和复发病例中均与最短生存相关。

关键数值与推荐

  • 预测单纯手术获得较长生存的MIB-1标记指数最佳临界值为低于4.0%。

临床怎么用

  • 作者认为脊髓星形细胞瘤的最佳治疗是在不造成神经功能损害的前提下最大程度切除肿瘤。
  • 作者认为当MIB-1标记指数低于4.0%且仍有肿瘤残留时,等待观察是最佳策略。
  • 作者推荐若MIB-1标记指数高于4.0%,可行局部放射治疗。
  • 作者不推荐辅助化疗用于II级脊髓星形细胞瘤的治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Primary spinal cord gliomas are rare, and among these astrocytomas (WHO grade II) are much rarer. The optimal treatment strategy thus remains unclear. The authors conducted a multicenter study led by the Neurospinal Society of Japan (NSJ) to analyze treatment policies and outcomes. The aim was to present optimal treatment methods for spinal cord astrocytoma and to identify predictors of better outcomes. METHODS: Among 1033 consecutive cases of spinal cord intramedullary tumors treated surgically at 58 centers affiliated with the NSJ, 57 patients were diagnosed with diffuse astrocytoma (WHO grade II) and were enrolled in the present study. Among these 57 patients, treatment methods, outcomes, and tumor proliferation rate as evaluated by the MIB-1 staining index (SI) were analyzed, and the optimal treatment method for spinal cord astrocytomas (grade II) was determined. In addition, the authors searched for factors predicting better treatment outcomes. RESULTS: Treatment for spinal cord astrocytoma comprised three methods: surgery alone in 30 patients, adjuvant radiation therapy in 13 patients, and adjuvant chemoradiotherapy in 13 patients. One patient who did not undergo surgery was excluded from survival analysis. Treatment with surgery alone or surgery with radiotherapy was associated with significantly longer overall and progression-free survivals than that with adjuvant chemoradiotherapy. Patients treated with radiation therapy had a higher MIB-1 SI than those treated with surgery alone. The extent of tumor resection tended to correlate with longer survival. In contrast, postoperative neurological worsening showed the inverse order. Adjuvant chemoradiotherapy was associated with the shortest survival in both total cases and recurrent cases. The optimal cutoff value of MIB-1 SI for predicting longer survival by surgery alone was less than 4.0%. CONCLUSIONS: The optimal treatment for spinal cord astrocytoma is maximal tumor resection without neurological impairment. When some tumor remains in patients with an MIB-1 SI less than 4.0%, a wait-and-see approach is optimal. If the MIB-1 SI is higher than 4.0%, local radiation therapy is recommended. Adjuvant chemotherapy is not recommended for the treatment of grade II spinal cord astrocytoma.

来源:J Neurosurg Spine,查看原文。版权归原作者所有。

引用

  1. Shigekawa S, Inoue A, Endo T, et al. Optimal treatment strategy for low-grade spinal cord astrocytoma: a retrospective, multicenter analysis by the Neurospinal Society of Japan. J Neurosurg Spine. 2024. PMID: 39303310. doi:10.3171/2024.5.SPINE24457

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。